

**BEST AVAILABLE COPY**

Applicants hereby designate the species with the following definitions:

B and E are each CH;

A or D is N while the other is CH;

T is CR<sub>4</sub>

R<sub>4</sub> is Cl, free, etherified or esterified hydroxy preferably OH or OMe, for this species

election R<sub>4</sub> is OMe;

G is C<sub>1</sub> alkylene;

and W is Me.

The species elected is represented by the Examples 47-48 and the compound on page 72 of the specification.

In addition, in response to the requirement to designate claims readable on the designated species, applicants further submit that claims 1-6, 9, and 17-21 are readable on the designated species.

The above designations are made with the understanding that this application is not limited to the designated species, and with the understanding that upon allowance of a claim generic to the designated species, applicants will be entitled to examination in this application of additional species.

Entry of this response is respectfully requested.

Respectfully submitted,



Lydia T. McNally  
Attorney for Applicants  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

Date: July 14, 2005